Product
K-877
5 clinical trials
4 indications
Indication
lipid metabolism disorderIndication
Severe HypertriglyceridemiaIndication
HypercholesterolemiaIndication
Type 2 DiabetesClinical trial
A Multicenter, Randomized, Open-Label, 4-Week Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Once Daily Treatment Compared to K-877-IR Twice Daily Treatment in Adult Patients With Fasting Triglyceride LevelsStatus: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal ImpairmentStatus: Completed, Estimated PCD: 2019-07-05
Clinical trial
A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Normal Renal FunctionStatus: Completed, Estimated PCD: 2019-06-24
Clinical trial
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)Status: Terminated, Estimated PCD: 2022-07-27